Compare LyondellBasell Industries NV (LYB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Neurocrine Biosciences Inc — how do they compare? LyondellBasell Industries NV trades at $60.34 (market cap $18.89B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 4.72% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LYB | NBIX | |
|---|---|---|
Market Cap | $18.89B | $14.60B |
Volume | 2,621,859 | 1,075,694 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $185.50 |
52-Week Low | $42.28 | $123.10 |
Typical Hold Time | 87 Days | 23 Days |
Enterprise Value | $30.48B | $14.61B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, amid a bearish technical signal and mixed fundamentals. The company reported a net loss of $745 million in 2025, with negative profit margins, though recent quarterly EPS beats and a consensus price target of $69.38 suggest recovery potential. Cash flow remains positive, and a $0.69 dividend is scheduled for payment on August 31, 2026, but declining revenue and high debt levels pose challenges.
The outlook for LYB hinges on earnings recovery and cost management, with analyst sentiment evenly split between buy and hold. Key risks include volatile chemical markets and high leverage, while institutional activity shows mixed positioning. The stock offers value based on P/S and P/B ratios but requires monitoring of profitability trends and debt sustainability for sustained upside.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
